HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coty/Balenciaga

This article was originally published in The Rose Sheet

Executive Summary

Coty inks deal with fashion house Balenciaga to develop and distribute fragrances under Balenciaga name, according to October 10 announcement. Partnership will renew Balenciaga's connection to fragrance - and allow it to "re-express" itself in the fragrance world - more than 60 years after launch of designer's Le Dix scent, company notes. Michele Scannavini, president of Coty Prestige, says Balenciaga's heritage "lends itself perfectly to Coty Prestige's designer portfolio" and acclaims Balenciaga as "a highly distinctive brand [that] embodies couture with a visionary style." Acquired by Gucci Group in 2001, Balenciaga currently creates men's and women's ready-to-wear, shoes and accessories and "is enjoying a very strong growth in all categories," according to the release

You may also be interested in...



Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Breakthrough Therapy Designations: Phase II Data Is Sweet Spot For US FDA Award

Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.

Medicare-For-Hmmm: A Year Of House Hearings Show Democratic Disunity

Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.

UsernamePublicRestriction

Register

RS015713

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel